Related Experiment Video

Updated: May 6, 2026

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs
10:44

Chemical Inactivation of the E3 Ubiquitin Ligase Cereblon by Pomalidomide-based Homo-PROTACs

Published on: May 15, 2019

13.0K

The clinical significance of cereblon expression in multiple myeloma

Steven R Schuster1, K Martin Kortuem2, Yuan Xiao Zhu2

  • 1Cancer Care and Hematology, University of Colorado Health, Fort Collins, CO, USA.

Leukemia Research
|October 17, 2013
PubMed

Insights

Very low Cereblon (CRBN) expression predicts resistance to immunomodulatory drugs (IMiDs) in multiple myeloma patients. Low CRBN levels are linked to poorer survival outcomes, while higher levels suggest a better prognosis.

Area of Science:

  • Oncology
  • Pharmacology
  • Molecular Biology

Background:

  • Cereblon (CRBN) is a key protein mediating the therapeutic effects of immunomodulatory drugs (IMiDs).
  • Understanding CRBN's role is crucial for predicting treatment response in multiple myeloma (MM).

Purpose of the Study:

  • To investigate the correlation between Cereblon (CRBN) expression levels and treatment outcomes in patients with refractory multiple myeloma (MM).
  • To determine if CRBN expression can serve as a predictive biomarker for response to IMiD therapy.

Main Methods:

  • Analysis of CRBN expression levels in 53 refractory multiple myeloma patients.
  • Correlation of CRBN expression quartiles with response rates, progression-free survival (PFS), and overall survival (OS) after treatment with pomalidomide and dexamethasone.

Main Results:

  • No patients with very low CRBN expression responded to IMiD plus dexamethasone therapy.
  • Patients in the lowest quartile of CRBN expression had significantly worse PFS (3.0 vs. 8.9 months) and OS (9.1 vs. 27.2 months) compared to those in the highest three quartiles.
  • Low CRBN expression was associated with decreased response rates to IMiD therapy.

Conclusions:

  • Cereblon (CRBN) expression level is a significant predictive biomarker for treatment response and survival outcomes in multiple myeloma patients receiving IMiD therapy.
  • Low CRBN expression predicts resistance to IMiD monotherapy and is associated with poor prognosis.
  • Higher CRBN levels may indicate lower risk disease and better survival outcomes.
Keywords:
Biological markersCereblonGene expression profilingImmunomodulatory drugsMultiple myeloma

More Related Videos

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells10:21

Proliferation and Differentiation of Murine Myeloid Precursor 32D/G-CSF-R Cells

Published on: February 21, 2018

9.3K
Cerebellar Regional Dissection for Molecular Analysis08:51

Cerebellar Regional Dissection for Molecular Analysis

Published on: December 5, 2020

4.4K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.0K